On August 28, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform will be presented at the CAR-TCR Summit 2018 being held from Sept. 4th – 7th, 2018 in Boston, MA (Press release, Endocyte, AUG 28, 2018, View Source [SID1234529171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Presentations and Symposia:
Chris Leamon, Ph.D., vice president of research at Endocyte, will lead a deep-dive workshop on the Company’s CAM-based therapies and their potential to induce an immune response while mitigating or preventing severe cytokine release syndrome.

Title: Bi-specific Adaptor Controlled CAR-T Cell Therapy for Solid and Liquid Tumors
When: Tuesday, Sept. 4, 2018 from 12:00 p.m. – 2:00 p.m. ET
Session Title: Deep Dive Discussion Day: CAR-TCR Discovery Track
Location: Cityview 1 Room (Seaport Hotel & World Trade Center)

Endocyte will also present a poster with new preclinical data from its CAM-based therapy platform.

Poster #: 15
Title: Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Immunotherapy: In-Vitro Activity and T-cell Exhaustion Studies
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Endocyte will also present two posters containing previously-presented preclinical data from its CAM-based therapy platform.

Poster #: 4
Title: Adaptor Controlled CAR-T Cell Immunotherapy for Treatment of Folate Receptor-Alpha/Beta Positive Solid and Liquid Tumors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Poster #: 5
Title: Regulation of CAR-T Cell Therapy in Real-Time Using Bispecific Small Molecule Adaptors in Monospecific Competitors
When: Thursday, Sept. 6, 2018 from 8:00 a.m. – 9:15 a.m. ET
Session Title: Scientific Poster Session
Location: Commonwealth Hall Salon C, Harbor Level (Seaport Hotel & World Trade Center)

Website Information:
Endocyte routinely posts important information intended for investors on its website, www.endocyte.com, in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in legal compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte’s website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, the Endocyte website is not incorporated by reference into, and is not a part of, this document.

On August 28, 2018 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that the Company will present on three panels at the B. Riley FBR Annual Healthcare Conference to be held on September 4, 2018 in New York City, as well as meeting with investors (Press release, Cellular Biomedicine Group, AUG 28, 2018, View Source [SID1234529160]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panels will range in topics from the latest development in CAR-T Cell Therapies to the role Chinese capital can play to fund innovation.

On August 28, 2018 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported that Marty Duvall, chief executive officer, will participate in a panel discussion titled, "Chinese Capital Meets Western Innovation" on Tuesday, September 4, at 11:20 a.m. Eastern Standard Time, at the B. Riley FBR Annual Healthcare Conference (Press release, Tocagen, AUG 28, 2018, View Source;p=RssLanding&cat=news&id=2365149 [SID1234529155]). In addition, Mr. Duvall will present a corporate overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Wednesday, September 5, at 9:35 a.m. Eastern Standard Time, also in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast from the H.C. Wainwright conference and subsequent replay may be accessed by visiting the "Events & Presentations" page in the investors section of Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 30 days following the presentation.

On August 28, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that Adelene Perkins, Infinity Pharmaceuticals’ Chief Executive Officer, and Lawrence Bloch, Infinity Pharmaceuticals’ President, will present at the following conferences (Press release, Infinity Pharmaceuticals, AUG 28, 2018, View Source [SID1234529119]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 20th Annual Global Investment Conferencein New York, NY on Wednesday September 5, 2018 at 1:45 p.m. ET

Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET

25th Annual BioCentury NewsMakers in the Biotech Industry in New York, NY on Friday, September 7, 2018 at 8:30 a.m. ET. Additionally, for those who will be attending BioCentury NewsMakers, Adelene Perkins will be participating in the lunch panel from 12:15 – 1:15 p.m. ET on "Investing In Hot Topics Areas" moderated by Simone Fishburn, BioCentury’s VP and Executive Editor.

A live webcast of the presentation for each of these conferences, excluding the BioCentury NewsMakers lunch panel discussion, will be available on the Investors/Media section of Infinity’s website at www.infi.com, and will be available for 30 days following the event.

On August 28, 2018 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that the company is scheduled to present at the Citi 13th Annual Biotech Conference in Boston on Wednesday, September 5, 2018 at 8:00 a.m. ET (Press release, Agios Pharmaceuticals, AUG 28, 2018, View Source [SID1234529116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.